COMPASS THERAPEUTICS

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

04 Oct 2024 09:31:45 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in Upcoming Investor Events

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

12 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer

06 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces CEO Transition

28 May 2024 15:10:20 By Nasdaq GlobeNewswire

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

23 May 2024 16:05:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

16 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

12 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

10 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

09 Apr 2024 11:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

21 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

29 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Provides Corporate Update

05 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

09 Nov 2023 06:30:00 By Nasdaq GlobeNewswire